ESWATINI
CERVICAL CANCER PROFILE

Morbidity and Mortality
Crude cervical cancer incidence per 100 000 women (2020): 57.8
Age-standardized cervical cancer incidence per 100 000 women (2020): 84.6
Cumulative risk of cervical cancer, ages 0-74 (2020): 8.6%
Cervical cancer deaths (2019): 210
Cervical cancer mortality-to-incidence ratio (2020): 0.63
Population-based cancer registry exists (2021): Yes

Primary Prevention
HPV vaccination programme coverage among girls (2020)

<table>
<thead>
<tr>
<th>Programme coverage*</th>
<th>Coverage by age 15 †</th>
</tr>
</thead>
<tbody>
<tr>
<td>no data</td>
<td>no data</td>
</tr>
</tbody>
</table>

HPV vaccination programme (2020):
HPV included in national vaccination programme: No
Scale of vaccination programme: -
Year of introduction: -
Primary target cohort: -

Related risk factors:
Tobacco use prevalence, women aged 15+ years (2020): 2%
Condom use at last high-risk sex (2006-2007): 60%
HIV incidence per 1000, women aged 15+ years (2020): 12.45

Secondary Prevention
National screening programme for cervical cancer exists (2021): Yes
Primary screening test used (2021): VIA
Target age range of programme (2021): 18-65 years
Programme/guidelines exist to strengthen early detection of first symptoms at primary health care level (2021): Yes
Clearly defined referral system exists from primary care to secondary and tertiary care (2021): Yes

Treatment and Supportive Care
National guidelines on cervical cancer management exist (2021): Yes

Cancer diagnosis and treatment services generally available (2021):
Cancer centre or cancer department at tertiary level: Yes
Pathology services (laboratories): Yes
Cancer surgery: Yes
Chemotherapy: Yes
Radiotherapy: No

Palliative care for patients with NCDs in the public health system generally available (2021):
In primary health care facilities: Yes
In community or home-based care: Yes

WHO Cervical Cancer Elimination Strategy Targets for 2030
90% of girls fully vaccinated with the HPV vaccine by the age of 15
70% of women are screened with a high-performance test by 35 years of age and again by 45 years of age
90% of women identified with cervical disease receive treatment

ND = data not available
VIA = Visual inspection with acetic acid

See Explanatory Notes for indicator descriptions.